The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma-Reference-Cited by-同舟云学术

The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma

Published:2018 Issue:2 Volume:58 Page:95-101
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Miyasato Yuko,Takashima Yasuo,Takeya Hiroto,Yano Hiromu,Hayano Azusa,Nakagawa Takenobu,Makino Keishi,Takeya Motohiro,Yamanaka Ryuya,Komohara Yoshihiro

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/58/2/58_18001/_pdf

Reference30 articles.

1. 1 Citterio G, Reni M, Gatta G et al. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017; 113: 97-110.

2. 2 Yamanaka R. Management of refractory or relapsed primary central nervous system lymphoma (Review). Mol Med Rep. 2009; 02: 879-885.

3. 3 Paydas S. Primary central nervous system lymphoma: essential points in diagnosis and management. Med Oncol. 2017; 34: 61.

4. 4 Makino K, Nakamura H, Yano S et al. Pediatric primary CNS lymphoma: longterm survival after treatment with radiation monotherapy. Acta Neurochir (Wien). 2007; 149: 295-298.

5. 5 Lionakis MS, Dunleavy K, Roschewski M et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017; 31: 833-843.e5.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis;Journal of Clinical Neuroscience;2024-06

2. Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis;Journal of Translational Medicine;2024-01-23

3. Updates of primary central nervous system lymphoma;Therapeutic Advances in Hematology;2024-01

4. Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy;Frontiers in Immunology;2023-11-13

5. Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer;Cancer Pathogenesis and Therapy;2023-11